{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T19:44:28Z","timestamp":1776800668768,"version":"3.51.2"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,3,31]],"date-time":"2011-03-31T00:00:00Z","timestamp":1301529600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Dermatol"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Vitiligo is the most prevalent pigmentary disorder which occurs worldwide, with an incidence rate between 0.1-4 percent. It is anticipated that the discovery of biological pathways of vitiligo pathogenesis will provide novel therapeutic and prophylactic targets for future approaches to the treatment and prevention of vitiligo. The purposes of this study were evaluating the efficacy of supplemental zinc on the treatment of vitiligo.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This randomized clinical trial was conducted for a period of one year. Thirty five patients among 86 participants were eligible to entrance to the study. The patients in two equal randomized groups took topical corticosteroid and combination of oral zinc sulfate-topical corticosteroid.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The mean of responses in the corticosteroid group and the zinc sulfate-corticosteroid combination group were 21.43% and 24.7%, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Although, the response to corticosteroid plus zinc sulfate was more than corticosteroid, there was no statistically significant difference between them. It appeared that more robust long-term randomized controlled trials on more patients, maybe with higher doses of zinc sulfate, are needed to fully establish the efficacy of oral zinc in management of vitiligo.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial Registration<\/jats:title>\n            <jats:p>chiCTRTRC10000930<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-5945-11-7","type":"journal-article","created":{"date-parts":[[2011,4,6]],"date-time":"2011-04-06T18:16:17Z","timestamp":1302113777000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Original article title: \"Comparison of therapeutic efficacy of topical corticosteroid and oral zinc sulfate-topical corticosteroid combination in the treatment of vitiligo patients: a clinical trial\""],"prefix":"10.1186","volume":"11","author":[{"given":"Reza","family":"Yaghoobi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Omidian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nooshin","family":"Bagherani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,3,31]]},"reference":[{"key":"111_CR1","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1001\/archderm.144.3.310","volume":"144","author":"SA Birlea","year":"2008","unstructured":"Birlea SA, Fain PR, Spritz RA: A Romanian population isolate with high frequency of vitiligo and associated autoimmune diseases. Arch Dermatol 2008, 144: 310\u2013316. 10.1001\/archderm.144.3.310","journal-title":"Arch Dermatol"},{"key":"111_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1001\/archderm.1977.01640010049006","volume":"113","author":"J Howitz","year":"1977","unstructured":"Howitz J, Brodthagen H, Schwartz M, Thomsen K: Prevalence of vitiligo. Arch Dermatol 1977, 113: 47\u201352. 10.1001\/archderm.113.1.47","journal-title":"Arch Dermatol"},{"key":"111_CR3","doi-asserted-by":"publisher","first-page":"206","DOI":"10.4103\/0378-6323.16243","volume":"71","author":"P Shameer","year":"2005","unstructured":"Shameer P, Prasad PVS, Kaviarasan PK: Serum zinc level in vitiligo: a case control study. Indian J Dermatol Venereol Leprol 2005, 71: 206\u2013207. 10.4103\/0378-6323.16243","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"111_CR4","first-page":"616","volume-title":"Fitzpatrick's Dermatology in General Medicine","author":"K Wolff","year":"2007","unstructured":"Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ: Fitzpatrick's Dermatology in General Medicine. Volume I. 7th edition. Mac Graw Hill; 2007:616\u2013621.","edition":"7"},{"key":"111_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1471-5945-6-3","volume":"6","author":"M Daneshpazhooh","year":"2006","unstructured":"Daneshpazhooh M, Mostofizadeh GM, Behjati J, Akhyani M, Mahmoud Robati R: Anti-thyroid peroxidase antibody and vitiligo: a controlled study. BMC Dermatol 2006, 6: 3. 10.1186\/1471-5945-6-3","journal-title":"BMC Dermatol"},{"key":"111_CR6","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1034\/j.1600-0749.2003.00032.x","volume":"16","author":"A Alkahateeb","year":"2003","unstructured":"Alkahateeb A, Fain PR, Thody A, Bennett DC, Spritz Ra: Epidemiology of vitiligo and associated autoimmune disease in Caucasian probands and their families. Pigment Cell Res 2003, 16: 208\u2013214. 10.1034\/j.1600-0749.2003.00032.x","journal-title":"Pigment Cell Res"},{"key":"111_CR7","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1529-8019.2008.00178.x","volume":"21","author":"L Torello","year":"2008","unstructured":"Torello L, Alessia G, Zanieri F, Colucci R, Moretti S: Vitiligo: new and emerging treatments. Dermatol Therapy 2008, 21: 110\u2013117. 10.1111\/j.1529-8019.2008.00178.x","journal-title":"Dermatol Therapy"},{"key":"111_CR8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/1721727X0600400103","volume":"4","author":"S Moretti","year":"2006","unstructured":"Moretti S, Amato L, Bellandi S, Fabbri P: Focus on vitiligo: a generalized skin disorder. Eur J Inflamm 2006, 4: 21\u201330.","journal-title":"Eur J Inflamm"},{"key":"111_CR9","first-page":"683","volume-title":"Treatment of Skin disease. omprehensive Therapeutic Strategies","author":"MG Lebwohl","year":"2006","unstructured":"Lebwohl MG, Heymann WR, Berth-Jones J, Coulson I: Treatment of Skin disease. omprehensive Therapeutic Strategies. 2nd edition. Mosby Elsevier; 2006:683\u2013687.","edition":"2"},{"key":"111_CR10","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.jaad.2008.06.023","volume":"59","author":"ME Whitton","year":"2008","unstructured":"Whitton ME, Ashcroft DM, Gonz\u00e1lez U: Therapeutic intervention for vitiligo. J Am Acad Dermatol 2008, 59: 713\u2013717. 10.1016\/j.jaad.2008.06.023","journal-title":"J Am Acad Dermatol"},{"key":"111_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/9780470750520","volume-title":"Rook's Textbook of Dermatology","author":"T Burns","year":"2004","unstructured":"Burns T, Breathnach S, Cox N, Griffiths C: Rook's Textbook of Dermatology. Volume 39. 7th edition. Oxford Blackwell Science; 2004:53\u201357.","edition":"7"},{"key":"111_CR12","first-page":"860","volume-title":"Clinical Dermatology","author":"WD James","year":"2006","unstructured":"James WD, Berger TG, Elston DM: Andrews Diseases of the Skin. In Clinical Dermatology. 10th edition. Saunders Elsivier; 2006:860\u2013863.","edition":"10"},{"key":"111_CR13","first-page":"242","volume":"20","author":"A Tonsi","year":"2004","unstructured":"Tonsi A: Vitiligo and its management update: A revew. Pak J Med Sci 2004, 20: 242\u2013247.","journal-title":"Pak J Med Sci"},{"key":"111_CR14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1471-5945-8-2","volume":"8","author":"O Szczurko","year":"2008","unstructured":"Szczurko O, Boon HS: A systematic review of natural heath product treatment for vitiligo. BMC Dermatol 2008, 8: 2. 10.1186\/1471-5945-8-2","journal-title":"BMC Dermatol"},{"issue":"6S","key":"111_CR15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1067\/mjd.2003.274","volume":"48","author":"RMMD Halder","year":"2003","unstructured":"Halder RMMD, Nootheti PKMD: Ethnic skin disorders overview. J Am Acad Dermatol 2003, 48(6S):143\u2013148. 10.1067\/mjd.2003.274","journal-title":"J Am Acad Dermatol"},{"key":"111_CR16","first-page":"51","volume":"17","author":"PN Behl","year":"1971","unstructured":"Behl PN, Bhatia RK: 400 cases of vitiligo - A clinicotherapeutic analysis. Indian J Dermatol 1971, 17: 51\u201353.","journal-title":"Indian J Dermatol"},{"key":"111_CR17","first-page":"145","volume":"61","author":"HR Mehta","year":"1973","unstructured":"Mehta HR, Shah KC, Theodore C: Epidemiological study of vitiligo in Surat area South Gujarat. Indian J Med Res 1973, 61: 145\u2013154.","journal-title":"Indian J Med Res"},{"key":"111_CR18","first-page":"913","volume-title":"Dermatology","author":"JL Bolognia","year":"2008","unstructured":"Bolognia JL, Jorizzo JL, Rapini R: Dermatology. Volume I. 2nd edition. Mosby Elsivier; 2008:913\u2013920.","edition":"2"},{"key":"111_CR19","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/j.1468-3083.2006.02106.x","volume":"21","author":"L Manolache","year":"2007","unstructured":"Manolache L, Benea V: Stress in patients with alopecia areata and vitiligo. J Europ Acad Dermatol Venereol 2007, 21: 921\u2013928. 10.1111\/j.1468-3083.2006.02106.x","journal-title":"J Europ Acad Dermatol Venereol"},{"key":"111_CR20","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S0377-1237(02)80083-1","volume":"58","author":"PN Arora","year":"2002","unstructured":"Arora PN, Dhillon KS, Rajan SR, Sayal SK, Das AL: Serum zinc level in cutaneous disorders. Med J of Armed Forces 2002, 58: 304\u2013306.","journal-title":"Med J of Armed Forces"},{"key":"111_CR21","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1111\/j.1525-1470.2007.00567.x","volume":"24","author":"AC Inamadar","year":"2007","unstructured":"Inamadar AC, Palit A: Acrodermatitis entropathica with depigmented skin lesions simulating vitiligo. Pediatr Dermatol 2007, 24: 668\u2013669. 10.1111\/j.1525-1470.2007.00567.x","journal-title":"Pediatr Dermatol"},{"key":"111_CR22","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1034\/j.1600-0749.2003.00070.x","volume":"16","author":"Y Gauthier","year":"2003","unstructured":"Gauthier Y, Cario Andre M, Taieb A: A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy? Pigment Cell Res 2003, 16: 322\u2013332.","journal-title":"Is melanocyte loss a melanocytorrhagy? Pigment Cell Res"},{"key":"111_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1471-5945-4-8","volume":"4","author":"SH Aghaei","year":"2004","unstructured":"Aghaei SH, Sodaifi M, Jafari P, Mazharinia , Finlay AY: DLQI scores in vitiligo: reliability and validity of the Persian version. BMC Dermatol 2004, 4: 8. 10.1186\/1471-5945-4-8","journal-title":"BMC Dermatol"},{"key":"111_CR24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1046\/j.1365-2133.2003.05097_9.x","volume":"148","author":"D Parsad","year":"2003","unstructured":"Parsad D, Pandhi R, Dogra S, Kanwar AJ, Kumar B: Dermatology life quality index score in vitiligo and its impact on the treatment outcome. Br J Dermatol 2003, 148: 373\u2013374. 10.1046\/j.1365-2133.2003.05097_9.x","journal-title":"Br J Dermatol"},{"key":"111_CR25","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1348\/000711299160077","volume":"72","author":"L Papadopoulos","year":"1999","unstructured":"Papadopoulos L, Bor R, Legg C: Coping with the disfiguring effects of vitiligo: a preliminary investigation into the effects of cognitive-behavioral therapy. Br J Med Psychol 1999, 72: 385\u2013396. 10.1348\/000711299160077","journal-title":"Br J Med Psychol"},{"key":"111_CR26","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/j.1610-0387.2007.06280.x","volume":"5","author":"T Forschner","year":"2007","unstructured":"Forschner T, Buchholtz S, Stockfleth E: Current state of vitiligo therapy-evidence based analysis of the literature. J Dtsch Dermatol Ges 2007, 5: 467\u2013475. 10.1111\/j.1610-0387.2007.06280.x","journal-title":"J Dtsch Dermatol Ges"},{"key":"111_CR27","first-page":"730","volume":"293","author":"PEMD Grimes","year":"2005","unstructured":"Grimes PEMD: New insights and new therapies in vitiligo. J Am Acad 2005, 293: 730\u2013735.","journal-title":"J Am Acad"},{"key":"111_CR28","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/lsm.20057","volume":"35","author":"N Ostovari","year":"2004","unstructured":"Ostovari N, Passeron T, Zakaria W, Fontas E, Larouy JC, Blot JF, et al.: Treatment of vitiligo by 308-nm excimer laser: an evaluation of variables affecting treatment response. Laser Surg Med 2004, 35: 152\u2013156. 10.1002\/lsm.20057","journal-title":"Laser Surg Med"},{"key":"111_CR29","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/j.1365-4362.1994.tb02903.x","volume":"33","author":"JS Pasricha","year":"1994","unstructured":"Pasricha JS, Khera V: Effect of prolonged treatment with levamisole on vitiligo limited and slow-spreading disease. Int J Dermatol 1994, 33: 584\u2013587. 10.1111\/j.1365-4362.1994.tb02903.x","journal-title":"Int J Dermatol"},{"key":"111_CR30","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/archderm.1983.01650330014006","volume":"119","author":"T Tsuji","year":"1983","unstructured":"Tsuji T, Hamada T: Topically administered fluorouracil in vitiligo. Arch Dermatol 1983, 119: 722\u2013727. 10.1001\/archderm.119.9.722","journal-title":"Arch Dermatol"},{"key":"111_CR31","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/labinvest.3780318","volume":"81","author":"R Van den wijngaard","year":"2001","unstructured":"Van den wijngaard R, Wankowicz-Kalinska A, Pals S, Weening J, Das P: Autoimmune melanocyte destruction in vitiligo. Lad Invest 2001, 81: 1061\u20131067.","journal-title":"Lad Invest"},{"key":"111_CR32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1001\/archderm.1977.01640010033003","volume":"113","author":"G Micha\u0451","year":"1977","unstructured":"Micha\u0451 G, Juhlin L, Vahlquist A: Effects of oral zinc and vitamin A in acne. Arch Dermatol 1977, 113: 31\u201336.","journal-title":"Arch Dermatol"},{"key":"111_CR33","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/j.1365-2133.1977.tb14277.x","volume":"97","author":"L Hillstrom","year":"1997","unstructured":"Hillstrom L, Pettersson L, Hellbe L, Kjellin A, Leczinsky C, Nordwall C: Comparison of oral treatment with zinc sulphate and placebo in acne vulgaris. Br J Dermatol 1997, 97: 681\u2013684. 10.1111\/j.1365-2133.1977.tb14277.x","journal-title":"Br J Dermatol"},{"key":"111_CR34","first-page":"117","volume":"54","author":"N Burrows","year":"1994","unstructured":"Burrows N, Turnbull A, Puchard N, Thompson R, Jones R: A trial of oral zinc supplementation in psoriasis. Cutis 1994, 54: 117\u2013118.","journal-title":"Cutis"},{"key":"111_CR35","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S0377-1237(02)80083-1","volume":"58","author":"PN Arora","year":"2002","unstructured":"Arora PN, Dhillon KS, Rajan SR, Sayal SK, Das AL: Serum zinc level in cutaneous disorders. Med J of Armed Forces 2002, 58: 304\u2013306.","journal-title":"Med J of Armed Forces"},{"key":"111_CR36","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0272-2712(18)30143-4","volume":"18","author":"s Chan","year":"1998","unstructured":"Chan s, Gerson B, Subramaniam S: The role of copper, molybdenum, selenium, and zinc in nutrition and health. Clin Lab Med 1998, 18: 673\u2013685.","journal-title":"Clin Lab Med"},{"key":"111_CR37","first-page":"1999","volume-title":"Martindle. The Complete Drug Reference","author":"SC Sweetman","year":"2009","unstructured":"Sweetman SC, Blake PS: Martindle. The Complete Drug Reference. Volume II. 36th edition. Everbest Printing Co; 2009:1999\u20132001.","edition":"36"}],"container-title":["BMC Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-5945-11-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-5945-11-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-5945-11-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-5945-11-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T13:26:56Z","timestamp":1630502816000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcdermatol.biomedcentral.com\/articles\/10.1186\/1471-5945-11-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,31]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["111"],"URL":"https:\/\/doi.org\/10.1186\/1471-5945-11-7","relation":{},"ISSN":["1471-5945"],"issn-type":[{"value":"1471-5945","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,31]]},"assertion":[{"value":"21 July 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"7"}}